



## 89bio to Participate in Upcoming Investor Conferences

June 16, 2021

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the following upcoming investor conferences in June:

- **SVB Leerink CybeRx Series: Liver Disease Day**  
Format: One-on-one investor meetings  
Date: Thursday, June 17, 2021
- **Raymond James Human Health Innovation Conference**  
Panel Discussion: *"State" of the Union: Current Thinking in NASH*  
Date: Wednesday, June 23, 2021 at 12:00 PM ET
- **Piper Sandler EASL Takeaway Day**  
Format: One-on-one investor meetings  
Date: Monday, June 28, 2021

### About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

### Investor Contact:

Ryan Martins  
Chief Financial Officer  
[investors@89bio.com](mailto:investors@89bio.com)

### Media Contact:

Peter Duckler  
773-343-3069  
[pduckler@w2ogroup.com](mailto:pduckler@w2ogroup.com)